About Us
About ReNewVax
ReNewVax is a next generation vaccine company developing therapeutic vaccines targeting some of the world’s most acute bacterial disease challenges.
Genomic Innovation for Global Protection
Exploiting a reverse vaccinology strategy, using genomic-led, rational discovery approaches ReNewVax has a pipeline of programs that offer protection beyond existing vaccines, opening up access and delivering a step-change in global health security.
RVX-001
Our lead program, RVX-001, is the first universal pneumococcal vaccine, targeting all ca. 100 serotypes of S. penumoniae.
By targeting all serotypes, with multiple antigens, any new variants that may arise in the future are also addressed, and long-term efficacy is maintained, overcoming the problem of waning efficacy faced by current pneumococcal vaccines.
Board of Directors
Neil Murray
CEO
Carolyn Horrocks
Board of Directors
Simon Cruwys
Board of Directors
Executive Team
Neil Murray
CEO
Simon Thorn
CFO
Miguel Leon-Rios
Head of Research
Patricia Barclay
Head of Legal